Paragonix Technologies
Paragonix Technologies, Inc., now a Getinge company, is a leading US-based medical device company specializing in advanced organ preservation and transport systems, aiming to set a new standard of care for transplantation globally. Founded in 2010 and headquartered in Massachusetts, Paragonix is recognized for its comprehensive portfolio of FDA-cleared and CE-marked devices that maintain a consistent, optimal thermal environment for donor organs, preventing exposure to damaging freezing temperatures. Their product line includes the SherpaPak Cardiac Transport System, the LIVERguard System, the BAROguard Donor Lung Preservation System, and the KidneyVault. Beyond preservation devices, Paragonix offers intuitive digital services, such as the VantagePoint organ tracking technology, which provides real-time location monitoring, temperature tracking, and logistics management via a centralized platform (the Paragonix App). This dual focus on advanced preservation technology and digital tools is designed to enhance procurement support, streamline workflows, and improve transplant outcomes across heart, lung, and liver procedures. The acquisition by Getinge AB in 2024 further strengthened the company’s commercial reach and global expansion in the organ preservation market.
Latest Market Research Report on Organ Preservation Download PDF Brochure Now
XVIVO Perfusion AB
XVIVO Perfusion AB, headquartered in Sweden, is a prominent, global market player deeply invested in organ preservation, with a strong focus on machine perfusion technologies. The company is known for developing improved products for organ perfusion, dedicating a substantial portion of its revenue to R\&D. XVIVO’s lung perfusion solution is considered a gold standard in the market, widely used in lung preservation procedures. The company’s innovative perfusion systems and solutions are designed to maintain organ viability for longer periods, enabling better assessment of organ function and potentially reducing organ discard rates. XVIVO has consistently expanded its offerings and addressable market through strategic acquisitions, such as the purchase of Organ Assist B.V. in 2020, further solidifying its leading position in ex-vivo machine perfusion technologies. Operating across Europe, Asia, the Middle East, and the Americas, XVIVO Perfusion AB is committed to advancing the field of transplantation by providing advanced, clinically proven solutions that lead to improved patient outcomes globally.
TransMedics
TransMedics, Inc. is a medical technology company focused on transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure. Founded in 1998 in Massachusetts, TransMedics is a key player in the organ preservation market, primarily known for its revolutionary Organ Care System (OCS). The OCS platform is a portable, life-sustaining technology that uses normothermic machine perfusion (NMP) to keep donor organs functioning in a near-physiologic state outside the body, unlike traditional static cold storage. This dynamic preservation method allows clinicians to actively assess the organ’s viability before transplantation, extending the preservation window and improving the utilization of marginal or extended-criteria donor organs. The OCS Heart, OCS Lung, and OCS Liver Systems have all received significant regulatory approvals, including FDA premarket approval (PMA). By providing a solution that facilitates better organ assessment and extends viability during transport, TransMedics is playing a critical role in expanding the donor pool and increasing the number of successful transplants worldwide.
Organ Recovery Systems
Organ Recovery Systems (ORS) is a medical device company that pioneered hypothermic machine perfusion for kidneys and has expanded its focus to include other organs. Founded in 1998, ORS is headquartered in Illinois and operates in over 17 countries, providing solutions designed for ultimate ease of use. Their flagship product is the LifePort Kidney Transporter, a device that provides a sealed, sterile environment where a specially formulated physiologic solution is gently pumped through the kidney at cold temperatures (Hypothermic Machine Perfusion or HMP) to minimize tissue damage. This technology has preserved and protected over 275,000 kidneys and is clinically validated to show significantly better graft survival rates compared to static cold storage. ORS also offers the LifePort Liver Transporter, which supports dynamic perfusion and static cold storage. All LifePort devices are equipped with specialized transmitters for precision monitoring and tracking, transmitting encrypted data and location details to a protected web portal, which streamlines case logistics and improves post-transplant outcomes.
Bridge to Life Limited
Bridge to Life Limited is a leading global provider of a comprehensive portfolio of organ preservation solutions and organ perfusion technology. The company offers premier products for both static cold storage and advanced machine perfusion techniques. A key part of their offering is the Belzer UW preservation solution, an internationally recognized solution for various solid organ transplantations. Furthermore, Bridge to Life is advancing machine perfusion with its VitaSmart Hypothermic Oxygenated Machine Perfusion System, which is focused on making Hypothermic Oxygenated Perfusion (HOPE) available to simplify the workstream for transplant centers and reduce hospital costs. Their commitment is centered on assessing organ viability, preserving more organs for transplantation, and ultimately saving more lives. The company actively collaborates with other key players, such as its partnership with Paragonix to merge preservation technologies with perfusion platforms, thereby expanding their collective offering across heart, lung, and liver preservation procedures, positioning Bridge to Life as a crucial provider in the evolving transplant ecosystem.
OrganOx Limited
OrganOx Limited, a University of Oxford spin-out company acquired by Terumo Corporation in 2025, is a global pioneer in the development of normothermic machine perfusion (NMP) technology. Co-founded by clinical academics in 2008, the company’s core innovation is the OrganOx metra® platform, a fully automated NMP system used to preserve and transport donor livers for transplantation. This technology is world-leading, capable of keeping donor organs functioning outside the body for significantly longer than traditional methods, with preservation times of up to 12 hours (or 24 hours in certain regions). By perfusing the organ at near-physiologic conditions, the metra system enables clinicians to more accurately evaluate organ function and confidently assess viability for transplant, thereby reducing organ discard rates and improving outcomes. The platform is approved for use with livers from both donors after brain death (DBD) and donors after circulatory death (DCD), and its FDA approval for operation during air transport expanded access to this life-saving technology globally.
Dr. Franz Köhler Chemie GmbH
Dr. Franz Köhler Chemie GmbH, based in Germany, is a well-established market player in the organ preservation field, with its origins dating back to 1959. The company has captured a substantial market share primarily through its flagship product, Custodiol® HTK (Histidin-Tryptophan-Ketoglutarate) solution. Custodiol is a widely used organ preservation solution that holds significant advantages over some other solutions, including reduced viscosity and an improved graft survival rate. Unlike some preservation solutions tailored to specific organs, Custodial is versatile, being widely used to preserve multiple organs including the heart, liver, kidney, and pancreas. The company’s expertise also extends to developing other medical products such as electrolyte and organ-protective solutions, therapeutics, and medical devices. Dr. Franz Köhler Chemie GmbH maintains a robust position in the global market by focusing on reliable, high-quality preservation solutions backed by an effective distribution network, securing its role as a key contributor to successful organ transplantation worldwide.
Essential Pharmaceuticals, LLC
Essential Pharmaceuticals, LLC is a US-based company that operates in the organ preservation market, focusing on developing and providing specialized preservation solutions. The company is recognized for its commitment to enhancing organ viability and improving transplant outcomes through its products. Essential Pharmaceuticals is consistently listed among the major and prominent players in the global organ preservation market, which highlights its substantial presence and importance in the development and distribution of the critical solutions required for the flushing, storage, and transport of donor organs before transplantation. The company’s role as a key provider of essential components in the organ preservation ecosystem supports transplant centers and hospitals in their life-saving work by ensuring organs are kept in optimal condition to maximize transplant success rates.
Terumo Corporation
Terumo Corporation is a global leader in medical innovation and technology, and its involvement in the organ preservation market is a result of a strategic expansion into this specialized sector. The company made a significant entry into organ transplantation-related devices by acquiring OrganOx Limited, a UK-based pioneer in normothermic machine perfusion (NMP) technology, in 2025 for a value of $1.5 billion. This acquisition brought the OrganOx metra® platform, a sophisticated NMP system for liver preservation, into the Terumo Group’s portfolio. By integrating OrganOx’s advanced technology, Terumo aims to utilize its global presence and resources to further advance and scale the use of dynamic organ preservation. This move signifies Terumo’s commitment to supporting next-generation preservation methods, such as NMP, which extend preservation times, allow for better functional assessment of marginal organs, and ultimately contribute to lower organ discard rates and improved transplant success rates globally.
Getinge AB
Getinge AB is a global medical technology company that provides equipment and systems for healthcare and life sciences, and its presence in the organ preservation market was significantly bolstered by a major strategic acquisition. In September 2024, Getinge acquired US-based Paragonix Technologies for $253 million, aiming to enter the rapidly evolving and high-growth market for advanced organ preservation and transportation. This acquisition instantly integrated Paragonix’s innovative line of organ preservation and transport systems, such as the SherpaPak and BAROguard devices, into Getinge’s comprehensive product offering. By making this strategic investment, Getinge now offers a complete solution that includes both static cold storage devices and digital tracking technology for organs like the heart, lung, and kidney. This move establishes Getinge as a key provider, leveraging its robust geographic presence and distribution channels to accelerate the global adoption of Paragonix’s clinically proven precision preservation technologies, thereby setting a new standard of care for transplantation worldwide.
Latest Market Research Report on Organ Preservation Download PDF Brochure Now